News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

Tonix Pharmaceuticals
|
June 20, 2022

How did the United States, a global superpower, get caught so flatfooted when the COVID-19 pandemic hit? A big reason was sleeping through the decline of domestic pharmaceutical manufacturing, allowing most development and manufacturing capabilities and jobs to leave the U.S. for foreign countries.

The University of Montana in Missoula and Montana State University in Bozeman have achieved “R1” designations for their research programs. The “R1” classification is conferred by the Carnegie Classification of Institutions of Higher Education organization based on factors including research expenditures, staffing, and number of doctorates awarded.

Montana State University Billings announces the launch of the Institute for Neurodiversity and Applied Behavior Analysis at the Montana Center for Inclusive Education (MCIE) on university campus. The Institute will serve children in the region with mental, social, and behavioral differences associated with autism spectrum disorders, developmental disabilities, similar mental health disorders, and other behavioral disabilities, by providing direct and telehealth clinical support.

BioScience Laboratories, a Nelson Labs company located in Bozeman, MT, and a leader in topical antimicrobial-product testing in the consumer, pharmaceutical, and medical-device industries, operates a biosafety-level-3 (BSL-3) laboratory that was inspected by the Centers for Disease Control and Prevention (CDC) last year. The CDC has since confirmed that the Bozeman facility’s BSL-3 lab and related procedures adequately meet guidelines for the company to test all common and concerning strains of SARS-CoV-2 and other potentially dangerous pathogens.

Last year, the World Trade Organization (WTO) proposed that biotechnology companies, including some in Montana, be required to give their formulas for COVID-19 vaccines to countries that aren’t as advanced as the U.S. in developing these technologies. The Biden administration has supported this proposal, but we have deep concerns about it.

ARTICLES OF INTEREST

When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.

National Institutes of Health
|
March 26, 2024

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

BIO.News
|
January 30, 2024

As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.

NIH National Institute on Aging
|
January 18, 2024

Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR

National Institutes of Health SEED
|
January 18, 2024

Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.

NEWSLETTER

Newsletter
|
May 7, 2024

View the Spring 2024 Newsletter now!

Newsletter
|
February 20, 2024

View the Winter II 2024 Newsletter now!